Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company based in Frederick, Maryland, United States. The company is focused on the development of mRNA-engineered cell therapies for the treatment of autoimmune diseases. Its approach leverages a novel mRNA platform to reprogram cells, aiming to expand the reach of cell therapy beyond oncology into autoimmune indications. The company describes itself as a leader in mRNA cell therapy and is dedicated to bringing treatments for autoimmune disorders into the 21st century. Cartesian Therapeutics emerged from a merger with Selecta Biosciences in November 2023. Following the merger, the combined company operates under the Cartesian Therapeutics name and is led by President, CEO, and Chairman Carsten Brunn, PhD, who previously served as President of Selecta. Brunn brings extensive pharmaceutical industry experience, having held senior leadership roles at Bayer, Eli Lilly, Novartis, Basilea, and Bausch & Lomb. The company's leadership team includes Chief Financial Officer Blaine Davis, among other executives. The company's pipeline is centered on mRNA cell therapies designed to treat autoimmune conditions. Its mission is to expand the reach of cell therapy to patients with autoimmune diseases, putting patients at the center of innovation. Cartesian Therapeutics is publicly traded, though its ticker symbol is not specified in the available evidence. The company maintains a corporate website at cartesiantherapeutics.com, where it provides information about its approach, pipeline, and commitment to patients. As a clinical-stage company, Cartesian Therapeutics is engaged in research and development activities, including clinical trials for its product candidates. Its headquarters in Frederick, Maryland, places it within the United States' prominent biotechnology corridor. The company's focus on mRNA cell therapy represents a novel approach in the autoimmune disease treatment landscape, potentially offering new therapeutic options for patients with conditions that currently have limited treatment alternatives.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that emerged from the merger of Cartesian Therapeutics and Selecta Biosciences in November 2023. The merger combined Selecta's immunology expertise and pipeline with Cartesian's mRNA cell therapy platform. Following the merger, the company adopted the Cartesian Therapeutics name and continued to be led by Carsten Brunn, PhD, who had served as President and CEO of Selecta prior to the merger. Brunn became President, CEO, and Chairman of the Board of the combined company. The company is headquartered in Frederick, Maryland, United States, a location known for its growing biotechnology sector. Cartesian Therapeutics focuses on developing mRNA-engineered cell therapies for autoimmune diseases, a novel approach that aims to expand the application of cell therapy beyond oncology. The company's platform is designed to reprogram cells using mRNA to treat autoimmune conditions, potentially offering new treatment options for patients with limited alternatives. Since the merger, Cartesian Therapeutics has continued to advance its pipeline of mRNA cell therapies. The company describes itself as a leader in mRNA cell therapy and is committed to bringing treatments for autoimmune disorders into the 21st century. Its mission is to expand the reach of cell therapy to patients with autoimmune diseases, with a focus on putting patients at the center of innovation. The company is publicly traded, although specific details about its listing and ticker symbol are not provided in the available evidence. Cartesian Therapeutics maintains a corporate website at cartesiantherapeutics.com, where it provides information about its approach, pipeline, leadership, and commitment to patients. The leadership team includes Carsten Brunn as President, CEO, and Chairman, and Blaine Davis as Chief Financial Officer, among other executives.

• Merger with Selecta Biosciences completed; company operates as Cartesian Therapeutics

Clinical-stage leader in mRNA cell therapy for autoimmune diseases

Product categories. mRNA cell therapies for autoimmune diseases

1. 1Home - Cartesian Therapeuticscartesiantherapeutics.com
2. 2About Us - Cartesian Therapeuticscartesiantherapeutics.com
3. 3Cartesian Therapeutics, Inc. (United States) - Wikidatawikidata.org